“That’s not spin, that’s stats.” — Robin Carhart-Harris, PhD, of Imperial College London, defending continued consideration of psilocybin (magic mushrooms) to treat depression despite negative results in a trial.
“What really breaks your heart is the ones that lost their jobs last night.” — Judy Davidson, DNP, RN, of the University of California San Diego, discussing research on suicide after job loss among nurses.
“We have long opposed those types of restrictions, because they do threaten access to care.” — Skye Perryman, JD, chief legal officer at the American College of Obstetricians and Gynecologists, on the FDA’s decision not to enforce the in-person prescribing requirement of abortion pill mifepristone (Mifeprex) during the pandemic.
“I think that this can help some people and I think that it would be incredibly meaningful to those people.” — Sandy Feng, MD, PhD, of the University of California San Francisco, voting in favor of allogeneic islet cell transplants for brittle type 1 diabetes at an FDA advisory committee meeting.
“We’ve been seeing not only existing clientele increase frequency because their symptoms of anxiety or depression have been worsening over the past year, but we’re also experiencing an unprecedented amount of new clients asking for help.” — Kathryn Esquer, PsyD, who created an online network for therapists transitioning into telehealth during the pandemic.
“Adoption in the United States would likely require additional studies here.” — Arvind Trindade, MD, of Long Island Jewish Medical Center at Northwell Health in New Hyde Park, New York, discussing trial results from India with a novel device for treating gastroesophageal reflux disease.